3 Specialty Branded Generics Company, Domestic Pharma Volume Leader and Overseas Formulations Maker Stocks With a Strong Future Roadmap: Ajanta Pharma, Mankind Pharma and Marksans Pharma
- October 28, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Ajanta Pharma, Mankind Pharma and Marksans Pharma: ROE of 11.7% to 23.3% and FY22 to FY26 revenue CAGR of 12.9% to 18.6%. Prices as of 27 Oct 2026.
Quick Answer
The three branded generic and formulation exporter stocks to watch are Ajanta Pharma, Mankind Pharma and Marksans Pharma. Their return on equity ranges from 11.7% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.9% to 18.6%. Ajanta Pharma has the highest return on equity at 23.3%, while Marksans Pharma has the fastest revenue growth at 18.6% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.
Branded generic and formulation exporter stocks let investors follow companies that serve a growing part of the Indian economy. Ajanta Pharma, Mankind Pharma and Marksans Pharma cover a specialty branded generics company, a domestic pharma volume leader and an overseas formulations maker.
This list covers three branded generic and formulation exporter stocks with complete current figures: Ajanta Pharma, Mankind Pharma and Marksans Pharma. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Branded Generic and Formulation Exporter Stocks?
Branded generic and formulation exporter stocks are listed pharmaceutical companies that sell branded generics in India and emerging markets and make over-the-counter and prescription formulations for developed markets. Their earnings depend on prescriptions, product launches, pricing and capacity use.
Branded Generic and Formulation Exporter Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Ajanta Pharma | 3,353.6 | 41,241 | 36.3 | 36.0 | 23.3 | 0.06 |
| Mankind Pharma | 2,502.5 | 93,014 | 45.0 | 36.0 | 11.7 | 0.39 |
| Marksans Pharma | 300.1 | 12,994 | 24.9 | 35.7 | 13.8 | 0.11 |
On valuation, Marksans Pharma trades at a P/E below the industry P/E, while Ajanta Pharma and Mankind Pharma trade above it, which reflects the growth the market already expects. Readers comparing branded generic and formulation exporter stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in branded generic and formulation exporter stocks can use the coming numbers to test whether growth is holding.
Why Do Branded Generic and Formulation Exporter Stocks Have a Strong Roadmap in India?
Branded generic and formulation exporter stocks have a strong roadmap in India because rising healthcare spending, wider medical access and growing demand for affordable medicines keep widening the market for Indian pharma companies.
- Prescription growth. Doctors prescribe more branded therapies.
- Domestic reach. Large field forces widen coverage.
- Overseas sales. Developed markets buy affordable formulations.
Why Ajanta Pharma Features Among These Branded Generic and Formulation Exporter Stocks
Among the branded generic and formulation exporter stocks on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.
In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%.
Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.
Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
What to watch: Monitor the pace of new launches in branded markets and the recovery trends in the United States generics business.
Why Mankind Pharma Features Among These Branded Generic and Formulation Exporter Stocks
Among the specialty and domestic pharma shares on this list, Mankind Pharma is one of India’s largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.
The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0.
Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore.
Roadmap: The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.
What to watch: Watch the market share in chronic therapies and the integration of acquired brands.
Why Marksans Pharma Features Among These Branded Generic and Formulation Exporter Stocks
Among the three companies on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.
Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%.
In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.
Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What to watch: Track export growth, new product approvals and plant utilisation.
Ajanta Pharma vs Mankind Pharma vs Marksans Pharma on Key Financials
The table below sets the three branded generic and formulation exporter stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Ajanta Pharma | 3,457 | 5,625 | 12.9% | 1,056 | 18.8% |
| Mankind Pharma | 7,978 | 14,636 | 16.4% | 1,938 | 13.2% |
| Marksans Pharma | 1,533 | 3,033 | 18.6% | 420 | 13.8% |
Ajanta Pharma posts the highest return on equity in this group at 23.3%. Mankind Pharma has the largest FY26 revenue at Rs 14,636 crore, and Marksans Pharma shows the fastest revenue growth with a 18.6% compound annual rate. A useful habit with branded generic and formulation exporter stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Ajanta Pharma | 1,329 | 1,697 | 27.7% |
| Mankind Pharma | 3,650 | 4,076 | 11.7% |
| Marksans Pharma | 626 | 866 | 38.5% |
Key Risks to Check Before Investing in Branded Generic and Formulation Exporter Stocks
Every theme carries risks that deserve a check before any decision. For these branded generic and formulation exporter stocks, the main points are: Long-term specialty and domestic pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect supply.
- Pricing rules. Medicine prices can follow policy changes.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter branded generic and formulation exporter stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Branded Generic and Formulation Exporter Stocks
Branded generic and formulation exporter stocks reward investors who follow demand trends, order books and margins together. Ajanta Pharma, Mankind Pharma and Marksans Pharma each have a clear plan to grow. Based on the 27 October 2026 close, Ajanta Pharma trades at Rs 3,353.6, Mankind Pharma at Rs 2,502.5 and Marksans Pharma at Rs 300.1. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these branded generic and formulation exporter stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track branded generic and formulation exporter stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are branded generic and formulation exporter stocks?
Ans. Branded generic and formulation exporter stocks are listed pharmaceutical companies that sell branded generics in India and emerging markets and make over-the-counter and prescription formulations for developed markets. Their earnings depend on prescriptions, product launches, pricing and capacity use. This list looks at three of them, Ajanta Pharma, Mankind Pharma and Marksans Pharma, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.
Which branded generic and formulation exporter stocks are covered in this list?
Ans. This list covers Ajanta Pharma, Mankind Pharma and Marksans Pharma. Based on the 27 October 2026 close, Ajanta Pharma traded at Rs 3,353.6, Mankind Pharma at Rs 2,502.5 and Marksans Pharma at Rs 300.1. Their return on equity ranges from 11.7% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.9% to 18.6%.
Why do branded generic and formulation exporter stocks have a strong future roadmap in India?
Ans. Branded generic and formulation exporter stocks have a strong roadmap in India because rising healthcare spending, wider medical access and growing demand for affordable medicines keep widening the market for Indian pharma companies. The main drivers are as follows. Prescription growth. Doctors prescribe more branded therapies. Domestic reach. Large field forces widen coverage. Overseas sales. Developed markets buy affordable formulations. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Ajanta Pharma performed financially?
Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
How has Mankind Pharma performed financially?
Ans. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.
How has Marksans Pharma performed financially?
Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What risks should investors check before buying branded generic and formulation exporter stocks?
Ans. Investors should check a few risks before buying branded generic and formulation exporter stocks. Regulatory checks. Plant inspections can affect supply. Pricing rules. Medicine prices can follow policy changes. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of branded generic and formulation exporter stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
